Danncan report Below extract from dancann annual report regarding Tbp deal.
the link to complete report is below also it is published for general meeting on apr 27:
https://mb.cision.com/Main/19875/3544780/1563600.pdf
Tetra Bio-Pharma Inc.
Furthermore, DanCann Pharma signed a definitive distribution agreement with Tetra Bio-Pharma Inc. for the exclusive distribution of ReduvoTM Adversa® and QixleefTM in Denmark, Norway, Sweden, Finland, and Germany, and hereby expanded its portfolio and
pipeline of unique medical cannabis products and pharmaceuticals.
The agreement encompasses a sum of upfront and milestone payments to Tetra of up to DKK 6.25 million and expected royalties to Tetra reaching up to DKK 62.5 million on DanCann Pharma’s peak sales for ReduvoTM Adversa®, QixleefTM and EnjoucaTM by 2028.
With this agreement DanCann Pharma is now entering into a completely new path around approved pharmaceuticals with cannabinoid-derived medicines, where restrictions are assumed to be minimal when approved. This provides DanCann Pharma with a portfolio of products, where the risk is widely spread and a much more transparent business plan and future tapping into the traditional way of introducing pharmaceutical products.
With the agreement with Tetra and DanCann Pharma’s strategy around IP-based cannabinoid drugs, the company is looking into a market in Germany, which today is worth more than DKK +1.25 billion, where approx. 80% of this is prescribed to the area for pain treatment and pain patients. A market that is strongly characterized by medical cannabis, and incredibly latent around actual cannabinoid drugs – like the rest of Europe – where today the market only have one other player in the market with EMA-approved cannabinoid drugs, and thus, this is not in direct competition with
the drugs covered by the distribution agreement with Tetra. Furthermore, DanCann Pharma also signed an exclusive agreement with Israelian Cannassure Therapeutics Ltd. for their medical cannabis product portfolio for the Scandinavian marke